WO2005082404A3 - Composes de glp-2, formulations et utilisations de ceux-ci - Google Patents

Composes de glp-2, formulations et utilisations de ceux-ci Download PDF

Info

Publication number
WO2005082404A3
WO2005082404A3 PCT/EP2005/050841 EP2005050841W WO2005082404A3 WO 2005082404 A3 WO2005082404 A3 WO 2005082404A3 EP 2005050841 W EP2005050841 W EP 2005050841W WO 2005082404 A3 WO2005082404 A3 WO 2005082404A3
Authority
WO
WIPO (PCT)
Prior art keywords
glp
lipophilic substituents
derivatives modified
compositions
derivatives
Prior art date
Application number
PCT/EP2005/050841
Other languages
English (en)
Other versions
WO2005082404A2 (fr
Inventor
Lars Thim
Original Assignee
Novo Nordisk As
Lars Thim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Lars Thim filed Critical Novo Nordisk As
Publication of WO2005082404A2 publication Critical patent/WO2005082404A2/fr
Publication of WO2005082404A3 publication Critical patent/WO2005082404A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Abstract

L'invention concerne des compositions comprenant des peptides 2 de type glucagon humain (GLP-2), des compositions pharmaceutiques et des utilisations de celles-ci et d'autres composés de GLP-2, des compositions et des formulations, notamment des méthodes permettant de traiter des troubles gastro-intestinaux et d'accroître l'absorption de nutriants au moyen de ceux-ci.
PCT/EP2005/050841 2004-02-27 2005-02-28 Composes de glp-2, formulations et utilisations de ceux-ci WO2005082404A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400321 2004-02-27
DKPA200400321 2004-02-27

Publications (2)

Publication Number Publication Date
WO2005082404A2 WO2005082404A2 (fr) 2005-09-09
WO2005082404A3 true WO2005082404A3 (fr) 2005-12-01

Family

ID=34895925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/050841 WO2005082404A2 (fr) 2004-02-27 2005-02-28 Composes de glp-2, formulations et utilisations de ceux-ci

Country Status (1)

Country Link
WO (1) WO2005082404A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023886B1 (ru) 2006-11-08 2016-07-29 Зеаланд Фарма А/С Селективные аналоги глюкагонподобного пептида-2 (glp-2)
WO2009033794A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
TR201802689T4 (tr) 2012-05-03 2018-03-21 Zealand Pharma As Glukagon benzeri peptit-2 (glp-2) analogları.
GB201315335D0 (en) * 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
BR112019010624A2 (pt) 2016-12-09 2019-10-22 Zealand Pharma As agonistas duplos de glp-1/glp-2 acilados e composição
EP3894387A4 (fr) * 2018-12-12 2023-07-19 Levim Biotech LLP Procédé d'acylation pour la préparation de peptide n-substitué
CN109836368B (zh) * 2019-03-14 2020-12-08 美药星（南京）制药有限公司 一种高纯度利拉鲁肽侧链的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0708179A2 (fr) * 1994-10-18 1996-04-24 Eli Lilly And Company Analogues de peptides insulinotropes de type glucagon, ocompositions et méthode d'utilisation
WO1996032414A1 (fr) * 1995-04-14 1996-10-17 1149336 Ontario Inc. Peptide-2 analogue au glucagon et ses utilisations therapeutiques
WO1998008872A1 (fr) * 1996-08-30 1998-03-05 Novo Nordisk A/S Derives de glp-2
WO2004035624A2 (fr) * 2002-10-14 2004-04-29 Novo Nordisk A/S Composes glp-2, leurs formulations et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0708179A2 (fr) * 1994-10-18 1996-04-24 Eli Lilly And Company Analogues de peptides insulinotropes de type glucagon, ocompositions et méthode d'utilisation
WO1996032414A1 (fr) * 1995-04-14 1996-10-17 1149336 Ontario Inc. Peptide-2 analogue au glucagon et ses utilisations therapeutiques
WO1998008872A1 (fr) * 1996-08-30 1998-03-05 Novo Nordisk A/S Derives de glp-2
WO2004035624A2 (fr) * 2002-10-14 2004-04-29 Novo Nordisk A/S Composes glp-2, leurs formulations et leurs utilisations

Also Published As

Publication number Publication date
WO2005082404A2 (fr) 2005-09-09

Similar Documents

Publication Publication Date Title
WO2006086562A3 (fr) Derives de phenylazetidinone
GEP20125565B (en) Lactam compounds and their pharmaceutical use
WO2007076085A3 (fr) Pyrimidones et thiopyrimidones fusionnees et leurs utilisations
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
WO2004092135A3 (fr) Composes therapeutiques
WO2007062078A3 (fr) Composes modulant l'activite thrombopoietine et procedes correspondants
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2007128817A3 (fr) Dérivé insulinique
WO2008070692A8 (fr) Composés chimiques et leurs utilisations
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
WO2005082404A3 (fr) Composes de glp-2, formulations et utilisations de ceux-ci
WO2006099169A3 (fr) Nouvelles compositions de liposomes
WO2007100366A3 (fr) Modulateurs allostériques positifs du récepteur de la quinolone m1
WO2006138608A3 (fr) Compositions pharmaceutiques et leur utilisation
WO2005037798A3 (fr) Nouveaux composés
WO2007105015A3 (fr) DÉRIVES D'ACIDE 18ß-GLYCYRRHETINIQUE
WO2007093880A3 (fr) Nouveaux dérivés d'indolopyrone et leur procédé de préparation
WO2005123043A3 (fr) Formulations de sumatriptan absorbables au travers des membranes biologiques, et methodes de production et d'utilisation desdites formulations
WO2008087365A3 (fr) Derives de 1,3-diphenylpropane substitues, preparations et utilisations
WO2007012479A3 (fr) Composes
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2005112923A3 (fr) Dérivés de 5-anilino-4-hétéroarylpyrazole utiles pour le traitement du diabete
WO2007070355A3 (fr) Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase